News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase II
Ardelyx (ARDX) To Present Phase 2 Data For Tenapanor In IBS-C Patients At The 2015 American College of Gastroenterology Annual Meeting 10/9/2015
Ansun BioPharma Announces Successful Treatment With DAS181 In A Patient With Severe Influenza And Parainfluenza At IDSA Meeting 10/9/2015
MediciNova, Inc. To Initiate Clinical Trial Of MN-001 (Tipelukast) In IPF 10/9/2015
Kuros Presents Results Of Phase IIB Study With KUR-111 At The 2015 Orthopaedic Trauma Association Annual Meeting 10/9/2015
Bavarian Nordic (BAVA.CO) Announces Initiation Of Safety And Immunogenicity Study Of Ebola Vaccine Regimen In Sierra Leone 10/9/2015
Celgene (CELG) Announces New Data For OTEZLA (Apremilast) Will Be Presented At European Academy Of Dermatology And Venereology Congress 10/9/2015
Nektar Therapeutics (NKTR) Reports On Advancements With Pain And Oncology Clinical Pipeline At Investor And Analyst R&D Day 10/9/2015
Nivalis Therapeutics Announces Positive Phase Ib Results For N91115 In Patients With Cystic Fibrosis And Plans To Initiate Phase II Trial 10/8/2015
Amgen (AMGN) Fights Fire with Fire in the Biosimilars Market 10/8/2015
Death Forces FDA to Place Clinical Hold on Advaxis (ADXS) Cancer Drug 10/8/2015
Synthetic Biologics, Inc. (SYN) Initiates Second SYN-010 Phase 2 Clinical Trial Intended To Treat Irritable Bowel Syndrome With Constipation (IBS-C) 10/8/2015
SynAgile Corporation Announces Positive Phase 2a Results For Continuous, Noninvasive, Intraoral Levodopa-Carbidopa Administration To Treat Parkinson's Disease 10/8/2015
Boehringer Ingelheim's Investigational Biologic Cleared Skin Better, Faster And For Longer Than Ustekinumab In Phase II Psoriasis Study 10/8/2015
Bionomics Limited (BNO.AX) Announces Extension Of Strategic Collaboration With Merck & Co. (MRK) For The Discovery And Development Of Novel Pain Medications 10/8/2015
Biocryst Pharmaceuticals (BCRX) Announces Completion Of Patient Enrollment In OPuS-2: A Clinical Trial Of Avoralstat In Patients With HAE 10/8/2015
Heat Biologics Completes Patient Enrollment For Randomized Arms Of Its Phase II HS-410 Bladder Cancer Trial 10/8/2015
VG Life Sciences, Inc. (VGLS) Notes Major Achievements And New Grants In Third Quarter 2015 10/8/2015
NuSirt Plans Clinical Trial In Non-Alcoholic Fatty Liver Disease 10/8/2015
Verona Pharma (VRP.L) Data Demonstrating PDE3/4 Inhibitor RPL554 Enhances CTFR-Dependent Currents In Cystic Fibrosis Airway Epithelia 10/8/2015
Nymox Pharmaceutical (NYMX) Announces Prostate Cancer Clinical Trial Will Complete Prospective 18 Month Post-Treatment Assessments 10/8/2015
Celtaxsys, Inc. Begins U.S. Enrollment For Phase 2 Trial Of Acebilustat Anti-Inflammatory Therapy For Cystic Fibrosis 10/8/2015
Genocea Biosciences (GNCA)'s GEN-003 Meets Primary Endpoint In Phase II Genital Herpes Trial 10/7/2015
Can-Fite BioPharma (CFBI) To Deliver 2 Presentations On Its Cancer Drug CF102 At The 20th World Congress On Advances In Oncology And 18th International Symposium On Molecular Medicine On October 8-10, 2015 In Athens 10/7/2015
Immune Pharmaceuticals, Inc. Submits Investigational New Drug Application (IND) In The U.S. For Its Lead Product Candidate Bertilimumab For The Treatment Of Bullous Pemphigoid 10/7/2015
Nektar Therapeutics (NKTR) Submits Investigational New Drug Application (IND) for NKTR-214 To Treat Solid Tumor Malignancies 10/7/2015
Dermira Presents Data From DRM01 Phase IIa Trial At European Academy Of Dermatology And Venereology 10/7/2015
BrainStorm Cell Therapeutics Inc. Announces Treatment Of Final Patient In US Multicenter Double Blinded Phase 2 ALS Trial 10/7/2015
RXi Pharmaceuticals (RXII) To Present At 14th Annual BIO Investor Forum 10/7/2015
Onxeo Announces Evolution In The Board Of Directors 10/7/2015
Opko Health (OPK) Presents Clinical Data On Its Long-Acting Human Growth Hormone (hGH-CTP) In Two Oral Presentations At The 54th Annual Meeting Of The European Society For Pediatric Endocrinology (ESPE) 10/7/2015
Acorda (ACOR) To Present New rHIgM22 and AMPYRA (dalfampridine) Data At The 31st Congress Of The European Committee For Treatment And Research In Multiple Sclerosis (ECTRIMS) 10/7/2015
Corbus Announces First Patient Dosed In Phase 2 Study Of Resunab For Systemic Sclerosis 10/7/2015
Merck KGaA (MKGAF.PK), Darmstadt, Germany, And Pfizer (PFE) Announce Investigational Immunotherapy Avelumab Receives FDA Fast Track Designation For Metastatic Merkel Cell Carcinoma 10/7/2015
PharmaCyte Biotech (NVLX) CEO In Europe To Secure Orphan Designation With The European Medicines Agency 10/7/2015
Anavex (AVXL) To Present Interim Phase 2a Clinical Trial Data Of ANAVEX 2-73 At Late-Breaking Oral Session Of CTAD 2015 Conference 10/7/2015
Ascend Announces Patients With Nodular Basal Cell Carcinoma Receives First Dose Of ASN-002 In Phase 1/2a Study 10/7/2015
Envisia Therapeutics' Lead Product Candidate, ENV515 (travoprost XR), Achieves Primary Efficacy Endpoint In Phase 2a Glaucoma Clinical Trial 10/6/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Completion Of Enrollment In Randomized Phase II Prostate Cancer Study 10/6/2015
Envisia Therapeutics' Lead Product Candidate, ENV515 (travoprost XR), Achieves Primary Efficacy Endpoint In Phase 2a Glaucoma Clinical Trial 10/6/2015
Tarix Pharmaceuticals Orphan Receives FDA Fast Track Designation For TXA127 As Potential Treatment For Duchenne Muscular Dystrophy 10/6/2015
MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) (MSHL) Announces Data From Phase II Clinical Studies Of Pracinostat Accepted For Oral Presentation At American Society of Hematology Annual Meeting 10/6/2015
Amgen (AMGN) To Give 23 Presentations On Osteoporosis Disease And Treatment At American Society For Bone And Mineral Research Annual Meeting 10/6/2015
Infinity Pharmaceuticals Inc. (INFI) To Provide Update On Duvelisib And Immuno-Oncology Development Candidate IPI-549 During 2015 Research And Development Day 10/6/2015
GTX Corp Announces Enrollment Of First Patient In Phase 2 Clinical Trial Of Enobosarm In Triple Negative Breast Cancer 10/6/2015
Clovis Oncology (CLVS) and AstraZeneca PLC (AZN) Duke it Out Over Lung and Ovarian Cancer Drugs 10/5/2015
Visterra, Inc.’s Monoclonal Antibody In Development For The Treatment Of Influenza A, VIS410, Demonstrated Significant Antiviral Activity And Reduced Duration Of Respiratory Symptoms In Phase IIa Challenge Study 10/5/2015
Invion Limited Successfully Completes Phase 2 Study Of INV102 (Nadolol) To Aid Smoking Cessation 10/5/2015
Biscayne Pharmaceuticals Merges With Insero Health, Adding Clinical-Stage Novel Epilepsy Program And Other CNS Assets 10/5/2015
PTC Therapeutics (PTCT) Release: Phase 2 Data From Spinal Muscular Atrophy Program To Be Presented At The 20th International Annual Congress Of The World Muscle Society 10/5/2015
RXi Pharmaceuticals (RXII) Bolsters Protection For Its Novel Self-Delivering RNAi Platform With Notice Of Allowance From USPTO 10/5/2015
ContraVir Pharmaceuticals Reports New Data Demonstrating CMX157 To Be 60-Fold More Potent Against Hepatitis B Virus Than Gilead (GILD)'s Viread 10/5/2015
Parion Sciences Announces Upcoming Presentations Of Data At The North American Cystic Fibrosis Conference Being Held October 8 Through 10, 2015 10/5/2015
OncoSec Medical Inc. To Present At Investment Conferences In October 10/5/2015
Viking Therapeutics (VKTX) To Present At Upcoming Investor Conferences 10/5/2015
Arrowhead Research Corporation (ARWR) To Present At Upcoming Conferences 10/5/2015
SanBio, Inc. Begins Recruiting Patients To Test Regenerative Treatment For Traumatic Brain Injury 10/5/2015
REPLICor Inc. Announces Initiation Of Recruitment For Its Phase IIb Clinical Trial With REP 2139-Mg Or REP 2165-Mg In Combination With Viread And Pegasys Or Zadaxin In Patients With Hbeag Negative Chronic Hepatitis B Infection 10/5/2015
Regulus (RGLS) To Present Updated Data Supporting RG-101 As Novel microRNA Therapeutic For The Treatment Of HCV At The Liver Meeting 2015 (AASLD) 10/2/2015
Data At SITC Annual Meeting To Highlight Progress Of Incyte (INCY)’s Immuno-Oncology Portfolio 10/2/2015
XBiotech USA (XBIT) Announces Publication Of Clinical Results Supporting The Potential Of Its True Human(TM) Antibody As A Cardiovascular Therapy 10/2/2015
Sarepta (SRPT) Announces Additional Long-Term Efficacy And Safety Data From Pivotal Phase IIb Program Of Eteplirsen For Treatment Of Duchenne Muscular Dystrophy 10/1/2015
Pharmalink AB Raises SEK100m To Advance Nefecon Development As New Treatment For Kidney Disease 10/1/2015
Synthetic Biologics, Inc. (SYN) Appoints Raymond Stapleton, PhD, As Senior Vice President, Manufacturing 10/1/2015
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives $500,000 Milestone Payment With Enrollment Of First Patient In U.S. Phase 2b/3 Dry Eye Trial 10/1/2015
Merck & Co. (MRK) And DNAtrix, Inc. Announce Phase II Immuno-Oncology Collaboration In Patients With Aggressive Form Of Brain Cancer 10/1/2015
Cerulean Pharma Inc. (CERU) Announces CRLX101 Advances To Second Stage Of Phase 2 Clinical Trial Of CRLX101 In Combination With Avastin In Relapsed Ovarian Cancer 9/30/2015
Important New Data From Teva (TEVA)'s TEV-48125 Phase IIB Migraine Program Published In Lancet Neurology In Back-To-Back Articles 9/30/2015
OncoGenex (OGXI) Announces Completion Of Patient Enrollment In Borealis-2 Clinical Trial Evaluating Apatorsen In Relapsed Or Refractory Metastatic Bladder Cancer 9/30/2015
Revance Therapeutics (RVNC) Initiates Phase II Clinical Study Of Its Unique Botulinum Toxin Type A For Injection To Treat Cervical Dystonia 9/30/2015
OXiGENE (OXGN) Announces Plans To Advance CA4P (Fosbretabulin) In Two Late-Stage Clinical Trials 9/30/2015
Phase II Trial Results Show Mesoblast (MSB.AX) Cell Therapy Has Greatest Cardioprotective Effect In Patients With Advanced Heart Failure 9/30/2015
Infinity Pharmaceuticals Inc. (INFI) Announces Enrollment Of 120th Patient In Phase 2 DYNAMO Study Evaluating Duvelisib In Indolent Non-Hodgkin Lymphoma 9/30/2015
BiondVax Pharmaceuticals Initiates A Phase Ilb Clinical Trial In Europe For Its Universal Flu Vaccine For Pandemic Outbreak 9/30/2015
Kura Oncology Initiates Phase II Study Of Tipifarnib In Peripheral T-Cell Lymphoma 9/30/2015
Caladrius Biosciences To Present Data Elucidating CLBS20 Mechanism of Action 9/30/2015
Dermira To Present Data For DRM01 Acne Program At EADV Congress 2015 9/30/2015
GenVec Inc. (GNVC) To Present At 2015 Stem Cell Meeting On The Mesa 9/30/2015
Data Supporting Delcath Systems (DCTH)'s Chemosat System Presented At The Cardiovascular and Interventional Radiology Society Annual Meeting 9/30/2015
Trevena, Inc. (TRVN) Announces Publication Of TRV130 Phase 2 Bunionectomy Data In The Journal PAIN 9/30/2015
Verastem (VSTM) Stops Study of Experimental Cancer Therapy; Stock Plunges 9/29/2015
Esperion (ESPR) Stock Plummets as Updates on ETC-1002 Prove Not Enough for Investors 9/29/2015
Novan Therapeutics Announces Successful Phase IIb Clinical Trial Results With SB204 For The Treatment Of Acne Vulgaris 9/29/2015
NeuralStem Inc. Investigator Provides Phase II Update On ALS Cell Therapy At American Neurological Association Annual Meeting 9/29/2015
HedgePath Pharmaceuticals Announces Commencement Of Patient Treatment In Its Phase II(b) Clinical Trial 9/29/2015
Aldeyra Therapeutics (ALDX) Announces First Patient Enrolled In Allergic Conjunctivitis Phase IIa Clinical Trial 9/29/2015
UbiVac Announces Collaboration With Johnson & Johnson Innovation (JNJ) To Develop And Test, In Preclinical Studies, A Vaccine To Intercept Oral Cancer 9/29/2015
RXi Pharmaceuticals (RXII) To Present At Dawson James Securities Growth Stock Conference 9/29/2015
Can-Fite BioPharma (CFBI) To Present CF101 Psoriasis Data At Late Breaking Session Of The EADV Congress In Copenhagen On October 10, 2015 9/29/2015
GTx, Inc. (GTXI) Announces Enrollment Of First Patient In Phase 2 Clinical Trial Of Enobosarm in ER+/AR+ Breast Cancer 9/29/2015
Medivation (MDVN) Release: Updated Enzalutamide Data In Triple-Negative Breast Cancer Presented At The 2015 European Cancer Congress 9/29/2015
Novavax (NVAX)'s RSV Vaccine Protect Infants via Maternal Immunization in Phase II Study 9/29/2015
DelMar Pharmaceuticals To Present Data On The Promising Potential Of VAL-083 In The Treatment Of Pediatric Brain Tumors 9/29/2015
RXi Pharmaceuticals (RXII) Granted Patent In China For Lead Clinical Candidate RXI-109 9/28/2015
Syndax And Merck & Co. (MRK) Announce First Patients Dosed In Phase 1b/2 Clinical Trial Of Entinostat And KEYTRUDA 9/28/2015
Afferent Pharmaceuticals Announces Positive Results In Phase 2b Chronic Cough Trial 9/28/2015
Two Positive Studies Of Genentech (RHHBY)’s Investigational Cancer Immunotherapy Atezolizumab In Specific Type Of Lung Cancer Presented At 2015 European Cancer Congress 9/28/2015
DelMar Pharmaceuticals To Present An Interactive Live Webcast At On October 1, 2015 9/28/2015
Synthetic Biologics, Inc. (SYN) Initiates SYN-004 Phase 2b Proof-of-Concept Clinical Trial 9/28/2015
OncoSec Medical Inc. Announces Positive Results From Phase II Trial Of ImmunoPulse IL-12 In Merkel Cell Carcinoma 9/28/2015
Vtesse, Inc. Initiates Phase 2b/3 Clinical Trial Of VTS-270 For Treatment Of Niemann-Pick Type C1 (NPC) Disease 9/28/2015
Eli Lilly (LLY)'s CYRAMZA (ramucirumab) Significantly Improves Progression-Free Survival In Phase II Bladder Cancer Trial 9/28/2015
VBL Therapeutics (VBLX) Reports Full Phase 2 Data From Clinical Trial Of VB-111 In Recurrent Glioblastoma (rGBM) At The ECC 2015 Conference, Meeting The Primary Endpoint Of Statistically-Significant Increase In Overall Survival 9/28/2015
Galena Biopharma  (GALE) Presents Positive GALE-301 Phase 2a Clinical Trial Data At The European Cancer Congress 2015 9/28/2015
Ansun BioPharma Announces CDC Publication Showing Potent Inhibitory Effects Of DAS181 On Enterovirus68 9/28/2015
Cellular Biomedicine Group (CBMG) Announces Positive Results From CAR-T EGFR Immunotherapy In Advanced Relapsed/Refractory Patients With Solid Tumors 9/28/2015
Genentech (RHHBY)'s New Drug Shows Benefits in Phase II Lung, Bladder Cancer Tests 9/28/2015
Viralytics Ltd (VLA.AX) Presents Phase 2 Melanoma Extension Cohort Data, Updated CALM Study Survival And CAVATAK/Immune Checkpoint Combination Preclinical Data At 2015 European Cancer Congress 9/28/2015
AEterna Zentaris (AEZS)' Zoptarelin Doxorubicin Meets Phase 2 Primary Endpoint In Men With Heavily Pretreated Castration And Taxane Resistant Prostate Cancer 9/28/2015
Array BioPharma, Inc. (ARRY) Release: Clinical Data Presented On Binimetinib And Encorafenib In Melanoma 9/28/2015
Mast Therapeutics (MSTX) Announces Presentation Of Results Of Nonclinical Study Of Vepoloxamer In Chronic Heart Failure At The HFSA's Annual Scientific Meeting 9/28/2015
Anavex (AVXL) Completes Patient Enrollment For Phase 2a Alzheimer’s Trial Ahead Of Schedule 9/28/2015
Pharmaleads Announces The Opening Of French Sites In Its International Phase IIa Clinical Study Of PL37 9/28/2015
BioTime (BTX)’s Subsidiary Cell Cure Neurosciences Ltd. Receives FDA Fast-Track Designation For Opregen For The Treatment Of The Dry Form Of Age-Related Macular Degeneration 9/28/2015
AbbVie (ABBV)'s Arthritis Drug Meets Primary Endpoint in Two Phase II Studies 9/25/2015
Conatus Pharma Soars on Positive Phase II Liver Cirrhosis Data 9/25/2015
Bellerophon Therapeutics (BLPH) Announces Positive Data From Interim Analysis Of Phase II Long-Term Extension Study Of Inopulse For Treatment Of Pulmonary Arterial Hypertension 9/25/2015
Sarepta (SRPT) Announces Corporate Update And Report On Recent Data From Phase Iib Study Of Eteplirsen For Duchenne Muscular Dystrophy 9/25/2015
Xencor To Present At Leerink Partners Inaugural Immuno-Oncology Roundtable 9/25/2015
OncoGenex (OGXI) Stock Plummets After Pancreatic Cancer Drug Misses Mark in Phase II Study 9/24/2015
Neovacs SA Initiates Phase IIb Trial Of Ifna-Kinoid For The Treatment Of Lupus 9/24/2015
Otonomy (OTIC)To Present Results For Auripro Phase III And OTO-104 Phase IIb Clinical Trials At 2015 AAO-HNSF Annual Meeting 9/24/2015
Galectin Therapeutics Begins Phase IIa Psoriasis Study With GR-MD-02 9/24/2015
Minerva Neurosciences, Inc. (NERV) Provides Update On Clinical Development Program With MIN-202, Selective Orexin-2 Receptor Antagonist 9/24/2015
Arrowhead Research Corporation (ARWR) Reports Peak Reduction In HBSAg Of Up To 99% (1.9 Log) After A Single Dose With Hepatitis B Candidate ARC-520 In Treatment Naïve Cohort Of Phase IIa Study 9/24/2015
Syros Pharmaceuticals Licenses Clinical-Stage Rara Agonist To Develop And Commercialize For Genomically-Defined Cancer Populations Identified By Gene Control Platform 9/24/2015
Mast Therapeutics (MSTX) To Host Analyst & Investor Day On October 7, 2015 9/24/2015
Xencor's Partner Initiates Phase 2 Clinical Trial Of A Biologic Candidate Using XmAb Cytotoxic Fc Domain 9/24/2015
Pulmatrix To Report Clinical Data On PUR0200 In Patients With Chronic Obstructive Pulmonary Disease 9/24/2015
Heron (HRTX) Surges After Pain Drug Succeeds in Phase II Study 9/23/2015
AVANIR Pharmaceuticals (AVNR) Announces JAMA Publication Of Phase II Study Results Showing AVP-923 Significantly Reduced Agitation In Patients With Alzheimer's Disease 9/23/2015
PharmaCyte Biotech (NVLX) Discusses Pancreatic Cancer Treatment For Upcoming Phase IIb Human Clinical Trial 9/22/2015
Genervon GM604 Reduced TDP-43 Protein Aggregates And Slowed Down ALS Progression 9/22/2015
Heron (HRTX) To Present Data From Completed Phase III MAGIC Study Of SUSTOL At ASCO Breast Cancer Symposium 9/22/2015
CytRx Corporation (CYTR) Announces The Publication Of Its Positive Global Phase 2b Clinical Trial Results For Soft Tissue Sarcoma In The Peer-Reviewed JAMA Oncology 9/22/2015
ZIOPHARM Oncology (ZIOP.OB) Announces Presentation Of Clinical And Preclinical Data From Ad-RTS-IL-12 At CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference 9/21/2015
Matinas BioPharma's MAT2203 -- Encochleated Formulation Of Amphotericin B -- Shows Potential To Target And Penetrate Tissue Infected With Invasive Candidiasis In Data Presented At ICAAC/ICC 2015 9/21/2015
SCYNEXIS, Inc. (SCYX) Presents Data Supporting The Potential Clinical Utility Of Antifungal Drug Candidate At ICAAC/ICC 2015 9/21/2015
CytoDyn Release: HIV Patients Successfully Reach One Year Of Virologic Suppression In PRO 140 Monotherapy Study 9/21/2015
Positive Topline Results Announced From Phase I/II Trial In Sanfilippo B Syndrome Patients Using uniQure (QURE)'s Novel AAV5-Based Gene Therapy 9/21/2015
Tolero Pharmaceuticals Announces Mechanistic Data Describing The Activity Of Alvocidib Within A Time-Sequential Regimen At Two Hematology Conferences 9/21/2015
Provectus Biopharmaceuticals Inc. Completes Patient Accrual For PH-10 Phase II Clinical Study Of Cellular And Immunologic Changes In The Skin 9/21/2015
BioInvent (BOVNF) And The University of Pennsylvania Enhance Planned Clinical Study With BI-505 9/21/2015
Sangamo BioSciences (SGMO) Reports Updated Clinical Data From ZFP Therapeutic Program For HIV/AIDS At The 2015 Interscience Conference Of Antimicrobial Agents And Chemotherapy 9/21/2015
Synthetic Biologics, Inc. (SYN) Reports First Analysis Demonstrating SYN-004's Ability To Protect The Microbiome From Damage Caused By IV Antibiotics In A Humanized Pig Model 9/21/2015
Corbus Commences Patient Enrollment In Phase 2 Clinical Study Of Resunab For The Treatment Of Cystic Fibrosis 9/21/2015
Advaxis, Inc.'s Axalimogene Filolisbac (ADXS-HPV) Showed 38.5 Percent 12-Month Survival In Patients With Persistent/Recurrent Metastatic Cervical Cancer 9/18/2015
TRACON Pharmaceuticals, Inc. (TCON) Reports Ongoing Complete Response In Choriocarcinoma Patient Treated With Company's TRC105 In Compassionate Use Phase 2 Clinical Trial Conducted At Dana-Farber Cancer Institute 9/18/2015
VBL Therapeutics (VBLX) To Present Complete Phase 2 Data On VB-111 In Combination With Bevacizumab In Recurrent GBM At The European Cancer Conference 9/18/2015
FDA Grants Qualified Infectious Disease Product Designation to Taksta Cempra Pharmaceuticals, Inc. (CEMP)'s Fusidic Acid Antibiotic 9/18/2015
Apricus Biosciences (APRI) Reports Top-Line Phase 2a Data For RayVa, Its Topical Treatment For Raynaud's Phenomenon 9/17/2015
Inovio Pharma (INO) Publishes Successful Phase 2b Trial Results Of Its HPV Immunotherapy In The Lancet Lancet 9/17/2015
Lion Biotechnologies, Inc. Announces Positive Updated Data From National Cancer Institute's Phase 2 Study of TIL Therapy in the Treatment of Metastatic Melanoma 9/17/2015
FDA Grants Fast Track Designation To Can-Fite BioPharma (CFBI)'s CF102 In The Treatment Of Liver Cancer 9/17/2015
Dimension Therapeutics Announces FDA Fast Track Designation For Lead Candidate DTX101 In Patients With Hemophilia B 9/17/2015
Infectious Disease Research Institute (IDRI) And Wellcome Trust Team For Tuberculosis Vaccine Trial In South Africa 9/17/2015
NW Bio (NWBO) Presenting New DCVax-Direct Poster At "The Inaugural International Cancer Immunotherapy Conference: Translating Science Into Survival" In New York City On Wednesday, September 16, 2015 9/16/2015
GW Pharma (GWPH) Surges on Positive Phase II Cannabis-Based Drug Study for Schizophrenia and Some Rare Diseases 9/16/2015
Geron Corporation (GERN) Announces Initiation Of Janssen Biotech Inc. (JNJ) Phase 2 Clinical Trial Of Imetelstat In Myelofibrosis 9/16/2015
Galectin Therapeutics Announces Start Of Phase 2 Clinical Trial With GR-MD-02 In NASH With Advanced Fibrosis 9/16/2015
Favorable Data On VistaGen Therapeutics, Inc.' AV-101 For Major Depressive Disorder Published In Peer-Reviewed Journal Of Pharmacology And Experimental Therapeutics 9/16/2015
Benitec (BLT.AX) Initiates A Fourth Site In Hepatitis C Clinical Trial 9/16/2015
RegeneRx Biopharmaceuticals, Inc. (RGRX) Announces First Patients Enrolled In Phase 2b/3 U.S. Dry Eye Clinical Trial With RGN-259 9/16/2015
Aquinox (AQXP) Announces Closing Of $98.0 Million Public Offering Of Common Stock, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares 9/16/2015
Transition Therapeutics Inc. (TTH.TO) Announces Fiscal 2015 Financial Results 9/16/2015
Heat Biologics To Present New Data On Its ComPACT Platform At The CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference 9/16/2015
XenoPort (XNPT)'s Shares Jump After Psoriasis Treatment Meets Phase II Primary Endpoint 9/15/2015
Raptor (RPTP)'s Phase IIb CyNCh Study Fails To Meet Primary Endpoint, Shares Skid 9/15/2015
TapImmune Inc. (TPIV) Vaccine To Be Studied In A $13.3 Million U.S. Department Of Defense Grant To Mayo Clinic For Phase II Clinical Trial In Triple Negative Breast Cancer 9/15/2015
ASLAN Pharmaceuticals Pte Ltd Receives Regulatory Approval In Singapore And Taiwan For The Phase 2 Study Of Aslan001 (Varlitinib) In Cholangiocarcinoma 9/15/2015
BeyondSpring Announces Positive Follow-Up Results For Phase 2 Trial Of Plinabulin In Advanced NSCLC At WCLC 2015 9/15/2015
BeyondSpring Announces Planned Start Of Phase I Investigator-Initiated Trial Of Plinabulin Plus Nivolumab, Enters Immuno-Oncology Space 9/15/2015
MerLion Pharmaceuticals Pte Ltd To Present Detailed Phase 2 Data On Efficacy Of Finafloxacin In Complicated Urinary Tract Infections At International Congress Of Chemotherapy And Infection (ICC) 9/15/2015
Ariad (ARIA) Announces Full Enrollment In Phase 2 ALTA Trial Of Brigatinib 9/15/2015
Adaptimmune To Participate In Two Upcoming Investor Conferences 9/15/2015
BioLife Solutions, Inc. (BLFS.OB) CryoStor Commercial Grade Freeze Media Embedded In TC Biopharm ImmuniCell Clinical Trial For Various Cancers 9/14/2015
Galena Biopharma  (GALE) To Present GALE-301 Phase 2a Clinical Trial Data At The European Society For Medical Oncology (ESMO) 9/14/2015
Sun Biomedical (ASX: SBN) Initiates Phase II Clinical Trial Of Promising Combination Therapy For Chronic Kidney Disease 9/14/2015
Amarantus Receives Orphan Drug Designation From The FDA For MANF For The Treatment Of Retinal Artery Occlusion 9/14/2015
Tolero Pharmaceuticals To Present Alvocidib Regimen Data At Upcoming Medical Conferences 9/14/2015
Catabasis Pharmaceuticals, Inc. Receives Rare Pediatric Disease Designation From FDA For Cat-1004 For The Potential Treatment Of Duchenne Muscular Dystrophy 9/14/2015
Vaccibody As Announces Vaccination Of First Patient In Its Phase I/IIa Study With VB10.16 Immunotherapy For Patients With HPV16 Induced High Grade Lesions Of The Cervix 9/14/2015
Lion Pharmaceuticals, Inc. Opens Enrollment In Phase 2 Study Of LN-144 For The Treatment Of Refractory Metastatic Melanoma 9/14/2015
Advaxis, Inc. Release: FDA Awards Grant For Phase 2 Study Of Axalimogene Filolisbac (ADXS-HPV) In HPV-Associated Head And Neck Cancer 9/14/2015
Innapharma Fifth DSMB Meeting Of The EffiKIR Trial Recommends Continuation Without Modification 9/14/2015
Array BioPharma, Inc. (ARRY) Announces Clinical Data Presentations At The 2015 European Cancer Congress 9/11/2015
Kite Pharma (KITE) Receives Positive Opinion For Orphan Drug Designation In The European Union For KTE-C19, Kite's Lead Cancer T-Cell Immunotherapy 9/11/2015
Novavax (NVAX) RSV F Vaccine Clinical Trial Data In Women Of Child Bearing Age Published In The Journal Of Infectious Disease 9/11/2015
Aridis Pharmaceuticals Receives FDA Fast Track Designation For AR-301 For Acute Pneumonia Caused By Staphylococcus Aureus 9/11/2015
Kerastem Hair Growth Data Presented At 2015 International Society of Hair Restoration Surgery (ISHRS) Annual Scientific Meeting 9/11/2015
Akebia Therapeutics, Inc. (AKBA) Announces Additions To Its Management Team 9/11/2015
BioCancell Receives FDA Fast Track Designation For BC-819 For Treatment Of Bladder Cancer Patients 9/11/2015
Flexion (FLXN) Tanks as Lead Drug Flunks Pivotal Phase IIb Clinical Trial 9/10/2015
Revance Therapeutics (RVNC) Initiates Phase II Clinical Trial Of Botulinum Toxin Type A Topical Gel To Treat Axillary Hyperhidrosis 9/10/2015
FDA Grants Fast Track Designation For MediciNova, Inc.'s MN-001 (Tipelukast) For The Treatment Of Idiopathic Pulmonary Fibrosis 9/10/2015
Summit Therapeutics Completes Targeted Enrolment For SMT19969 Phase II Trial For C. Difficile Infection 9/10/2015
Versartis, Inc. (VSAR) Initiates Phase II Trial (VITAL) Of Monthly Somavaratan In Adults With Growth Hormone Deficiency 9/10/2015
Lori Kunkel, M.D., Joins Tocagen Inc.'s Board Of Directors 9/10/2015
Skin Disposition Study Results For Dermira's DRM01 Program In Acne Presented At International Dermatology Meeting 9/10/2015
Trevi Therapeutics Announces Positive Results From Phase II/III Trial In Uremic Pruritus 9/10/2015
BioLineRx Ltd. Announces Regulatory Submission For Phase 2 Trial Of BL-8040 As Novel Treatment For Hypoplastic Myelodysplastic Syndrome And Aplastic Anemia 9/10/2015